Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-32: Elranatamab vs EPd, PVd, or Kd in Relapsed/Refractory Multiple Myeloma
jRCT2021230055Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of elranatamab in multiple myeloma (MM) (4 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Apr 2024; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2021230055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230055.